Myeloma Canada is excited to announce that price negotiations between the pan-Canadian Pharmaceutical Alliance (pCPA) and the manufacturer of teclistamab (Tecvayli) have concluded successfully! This means teclistamab can now be reimbursed by public drug plans and listed on provincial formularies. A letter of intent has been issued (a price agreement reached) for the following indication: 

• Adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.   

After receiving positive reimbursement recommendations in 2024 from the Canadian Drug Agency (CDA-AMC) and the Institut national d’excellence en santé et en services sociaux (INESSS), pCPA negotiations began in October 2024, and were concluded on April 16, 2025. We are thrilled that teclistamab reimbursement (under these conditions) is nearly a reality for Canadians!*  

In fact, Quebec has already listed teclistamab on the “Liste des médicaments fournis en établissement” [List of medications administered in institutions].

Myeloma Canada will continue to advocate for our community’s needs and work closely with interested parties to support bringing this new treatment to each province and territory.   

*As public funding becomes available in each province, we will announce these updates here in the News section of myeloma.ca, in our Myeloma Matters e-newsletter, and updates will be reflected in our Drug Access Navigator tool.